BACKGROUND: Placenta previa is the abnormal implantation of the placenta into the lower segment of the uterus, is associated with adverse maternal and fetal outcomes such as placenta accreta spectrum disorders, antepartum and postpartum hemorrhage, fetal growth restriction, prematurity, stillbirth and neonatal death, thrombophlebitis, and septicemia. The aim of the study was to assess retrospectively how the later onset of placenta previa affects the microRNA expression profile in the whole peripheral blood during the first trimester of gestation. METHODS: Regarding the occurrence of the association between aberrant microRNA expression profiles at early stages of gestation and later onset of various pregnancy-related complications, we selected for the study pregnancies developing placenta previa as the only pregnancy-related disorder. In total, 24 singleton pregnancies diagnosed with placenta previa that underwent first-trimester prenatal screening and delivered on-site within the period November 2012-May 2018 were included in the study. Overall, 80 normal pregnancies that delivered appropriate-for-gestational age newborns after completing 37 weeks of gestation were selected as the control group based on the equality of the length of biological sample storage. RESULTS: Downregulation of multiple microRNAs (miR-20b-5p, miR-24-3p, miR-26a-5p, miR-92a-3p, miR-103a-3p, miR-130b-3p, miR-133a-3p, miR-145-5p, miR-146a-5p, miR-155-5p, miR-181a-5p, miR-195-5p, miR-210-3p, miR-342-3p, and miR-574-3p) was observed in pregnancies destined to develop placenta previa. The combination of seven microRNAs (miR-130b-3p, miR-145-5p, miR-155-5p, miR-181a-5p, miR-210-3p, miR-342-3p, and miR-574-3p) showed the highest accuracy (AUC 0.937, p < 0.001, 100.0% sensitivity, 83.75% specificity) to differentiate, at early stages of gestation, between pregnancies with a normal course of gestation and those with placenta previa diagnosed in the second half of pregnancy. Overall, 75% of pregnancies destined to develop placenta previa were correctly identified at 10.0% FPR. CONCLUSION: Consecutive large-scale analyses must be performed to verify the reliability of the proposed novel early predictive model for placenta previa occurring as the only pregnancy-related disorder.

Department of Molecular Biology and Cell Pathology 3rd Faculty of Medicine Charles University Prague Czechia

Institute for the Care of the Mother and Child 3rd Faculty of Medicine Charles University Prague Czechia

Zobrazit více v PubMed

Bi S, Zhang L, Wang Z, Chen J, Tang J, Gong J, et al. . Effect of types of placenta previa on maternal and neonatal outcomes: a 10-year retrospective cohort study. Arch Gynecol Obstet. (2021) 304:65–72. doi: 10.1007/s00404-020-05912-9, PMID: PubMed DOI

Sahu SA, Shrivastava D. Maternal and perinatal outcomes in placenta Previa: a comprehensive review of evidence. Cureus. (2024) 16:e59737. doi: 10.7759/cureus.59737, PMID: PubMed DOI PMC

Jansen CHJR, Kastelein AW, Kleinrouweler CE, Van Leeuwen E, De Jong KH, Pajkrt E, et al. . Development of placental abnormalities in location and anatomy. Acta Obstet Gynecol Scand. (2020) 99:983–93. doi: 10.1111/aogs.13834, PMID: PubMed DOI PMC

Karami M, Jenabi E, Fereidooni B. The association of placenta previa and assisted reproductive techniques: a meta-analysis. J Matern Fetal Neonatal Med. (2018) 31:1940–7. doi: 10.1080/14767058.2017.1332035, PMID: PubMed DOI

Hessami K, Mitts M, Zargarzadeh N, Jamali M, Berghella V, Shamshirsaz AA. Ultrasonographic cervical length assessment in pregnancies with placenta previa and risk of perinatal adverse outcomes: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. (2024) 6:101172. doi: 10.1016/j.ajogmf.2023.101172, PMID: PubMed DOI

Hu H, Wang L, Gao J, Chen Z, Chen X, Tang P, et al. . Risk factors of severe postpartum hemorrhage in pregnant women with placenta previa or low-lying placenta: a retrospective cohort study. BMC Pregnancy Childbirth. (2024) 24:674. doi: 10.1186/s12884-024-06876-3, PMID: PubMed DOI PMC

Kumari U, Naniwal A, Rani V, Chandat R, Yadav S, Pipal DK. A study of clinical characteristics, demographic characteristics, and fetomaternal outcomes in cases of placenta Previa: an experience of a tertiary care center. Cureus. (2022) 14:e32125. doi: 10.7759/cureus.32125, PMID: PubMed DOI PMC

Jenabi E, Salimi Z, Bashirian S, Khazaei S, Ayubi E. The risk factors associated with placenta previa: an umbrella review. Placenta. (2022) 117:21–7. doi: 10.1016/j.placenta.2021.10.009, PMID: PubMed DOI

Pun I, Singh A. Feto-maternal outcomes in placenta Previa with and without previous cesarean section. J Nepal Health Res Counc. (2022) 20:142–6. doi: 10.33314/jnhrc.v20i01.3640, PMID: PubMed DOI

Post RJ, Chang J, Ziogas A, Crosland BA, Silver RM, Haas DM, et al. . Risk factors and perinatal outcomes for persistent placenta previa in nulliparas. Am J Obstet Gynecol MFM. (2023) 5:101136. doi: 10.1016/j.ajogmf.2023.101136, PMID: PubMed DOI

Jain V, Bos H, Bujold E. Guideline No. 402: diagnosis and Management of Placenta Previa. J Obstet Gynaecol Can. (2020) 42:906–917.e1. doi: 10.1016/j.jogc.2019.07.019, PMID: PubMed DOI

Bhide A. Routine screening for placenta accreta spectrum. Best Pract Res Clin Obstet Gynaecol. (2023) 90:102392. doi: 10.1016/j.bpobgyn.2023.102392, PMID: PubMed DOI

Dar P, Doulaveris G. First-trimester screening for placenta accreta spectrum. Am J Obstet Gynecol MFM. (2024) 6:101329. doi: 10.1016/j.ajogmf.2024.101329, PMID: PubMed DOI

Lai EC. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet. (2002) 30:363–4. doi: 10.1038/ng865, PMID: PubMed DOI

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. (2004) 116:281–97. doi: 10.1016/s0092-8674(04)00045-5 PubMed DOI

Piletič K, Kunej T. MicroRNA epigenetic signatures in human disease. Arch Toxicol. (2016) 90:2405–19. doi: 10.1007/s00204-016-1815-7, PMID: PubMed DOI

Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. (2016) 231:25–30. doi: 10.1002/jcp.25056, PMID: PubMed DOI PMC

Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, et al. . miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells. (2020) 9:276. doi: 10.3390/cells9020276, PMID: PubMed DOI PMC

Hromadnikova I, Kotlabova K, Krofta L. Cardiovascular disease-associated MicroRNA dysregulation during the first trimester of gestation in women with chronic hypertension and normotensive women subsequently developing gestational hypertension or preeclampsia with or without fetal growth restriction. Biomedicines. (2022) 10:256. doi: 10.3390/biomedicines10020256, PMID: PubMed DOI PMC

Hromadnikova I, Kotlabova K, Krofta L. First-trimester screening for fetal growth restriction and small-for-gestational-age pregnancies without preeclampsia using cardiovascular disease-associated MicroRNA biomarkers. Biomedicines. (2022) 10:718. doi: 10.3390/biomedicines10030718, PMID: PubMed DOI PMC

Hromadnikova I, Kotlabova K, Krofta L. First trimester prediction of preterm delivery in the absence of other pregnancy-related complications using cardiovascular-disease associated MicroRNA biomarkers. Int J Mol Sci. (2022) 23:3951. doi: 10.3390/ijms23073951, PMID: PubMed DOI PMC

Hromadnikova I, Kotlabova K, Krofta L. Cardiovascular disease-associated MicroRNAs as novel biomarkers of first-trimester screening for gestational diabetes mellitus in the absence of other pregnancy-related complications. Int J Mol Sci. (2022) 23:10635. doi: 10.3390/ijms231810635, PMID: PubMed DOI PMC

Hromadnikova I, Kotlabova K, Krofta L. First-trimester screening for HELLP syndrome-prediction model based on MicroRNA biomarkers and maternal clinical characteristics. Int J Mol Sci. (2023) 24:5177. doi: 10.3390/ijms24065177, PMID: PubMed DOI PMC

Hromadnikova I, Kotlabova K, Krofta L. First-trimester screening for miscarriage or stillbirth-prediction model based on MicroRNA biomarkers. Int J Mol Sci. (2023) 24:10137. doi: 10.3390/ijms241210137, PMID: PubMed DOI PMC

Hromadnikova I, Kotlabova K, Krofta L. First-trimester predictive models for adverse pregnancy outcomes—a base for implementation of strategies to prevent cardiovascular disease development. Front Cell Dev Biol. (2024) 12:1461547. doi: 10.3389/fcell.2024.1461547, PMID: PubMed DOI PMC

Haynes W. Benjamini–Hochberg Method In: Dubitzky W, Wolkenhauer O, Cho KH, Yokota H, editors. Encyclopedia of systems biology. New York, NY: Springer; (2013)

Hasegawa Y, Miura K, Higashijima A, Abe S, Miura S, Yoshiura K, et al. . Increased levels of cell-free miR-517a and decreased levels of cell-free miR-518b in maternal plasma samples from placenta Previa pregnancies at 32 weeks of gestation. Reprod Sci. (2015) 22:1569–76. doi: 10.1177/1933719115589407, PMID: PubMed DOI

Timofeeva AV, Fedorov IS, Pirogova MM, Vasilchenko ON, Chagovets VV, Ezhova LS, et al. . Clusterin and its potential regulatory microRNAs as a part of Secretome for the diagnosis of abnormally invasive placenta: Accreta, increta, and Percreta cases. Life. (2021) 11:270. doi: 10.3390/life11040270, PMID: PubMed DOI PMC

Munoz JL, Einerson BD, Silver RM, Mulampurath S, Sherman LS, Rameshwar P, et al. . Serum exosomal microRNA pathway activation in placenta accreta spectrum: pathophysiology and detection. AJOG Glob Rep. (2024) 4:100319. doi: 10.1016/j.xagr.2024.100319, PMID: PubMed DOI PMC

Chen S, Pang D, Li Y, Zhou J, Liu Y, Yang S, et al. . Serum microRNA biomarker discovery for placenta accreta spectrum. Placenta. (2020) 101:215–20. doi: 10.1016/j.placenta.2020.09.068, PMID: PubMed DOI